SEMA4 | Jotup

CM Life Sciences and Sema4 Announce Release of Definitive Proxy Statement for July 21 Shareholder Meeting to Vote on Business Combination

Retrieved on:

Friday, July 2, 2021

Data management, Health, Technology, Genetics, Other Science, General Health, Science, SEC filings, Shareholders, Proxy statement, Statements, Proxy, CM Life Sciences, Sema4, CM LIFE SCIENCES, SEMA4

The definitive proxy statement contains important information about the proposed business combination contemplated by the Agreement and Plan of Merger dated February 9, 2021, by and between CM Life Sciences and Sema4.

Key Points:

The definitive proxy statement contains important information about the proposed business combination contemplated by the Agreement and Plan of Merger dated February 9, 2021, by and between CM Life Sciences and Sema4.
All stockholders of CM Life Sciences are strongly encouraged to review the definitive proxy statement and to vote as soon as possible in advance of the special meeting.
Neither Sema4 nor CM Life Sciences gives any assurance that either Sema4 or CM Life Sciences or the combined company will achieve its expectations.
Information about CM Life Sciences directors and executive officers and their ownership of CM Life Sciences securities is set forth in CM Life Sciences filings with the SEC.

Sema4 and CM Life Sciences Announce the Filing of Amended Preliminary Proxy Statement

Retrieved on:

Thursday, June 10, 2021

The filing of the amended proxy statement marks the next step in the formal Securities and Exchange Commission (SEC) review process required to finalize the definitive proxy statement that will be sent to CM Life Sciences shareholders.

Key Points:

The filing of the amended proxy statement marks the next step in the formal Securities and Exchange Commission (SEC) review process required to finalize the definitive proxy statement that will be sent to CM Life Sciences shareholders.
Neither Sema4 nor CM Life Sciences gives any assurance that either Sema4 or CM Life Sciences or the combined company will achieve its expectations.
In connection with the proposed transaction, CM Life Sciences has filed an amended preliminary proxy statement with the SEC, and CM Life Sciences will file a definitive proxy statement with the SEC, which will be sent to the stockholders of CM Life Sciences.
Information about CM Life Sciences directors and executive officers and their ownership of CM Life Sciences securities is set forth in CM Life Sciences filings with the SEC.

AdventHealth and Sema4 Launch a Data-driven Precision Medicine Program to Optimize Patient Care and Outcomes

Retrieved on:

Tuesday, May 25, 2021

General Health, Health, Data management, Technology, Software, AdventHealth, Precision medicine, Florida, Celebration, Florida, Healthcare in the United States, Health care, AdventHealth Orlando, Community Health Systems, AdventHealth Celebration, the AdventHealth Central Florida Division, Sema4, THE ADVENTHEALTH CENTRAL FLORIDA DIVISION, SEMA4

Initially, AdventHealth and Sema4 will focus on accelerating research in AdventHealths Orlando-area network, which includes more than 20 hospitals and emergency departments, and accounts for more than two million patient visits annually.

Key Points:

Initially, AdventHealth and Sema4 will focus on accelerating research in AdventHealths Orlando-area network, which includes more than 20 hospitals and emergency departments, and accounts for more than two million patient visits annually.
Nationally, the company has 50 hospitals and hundreds of care sites across almost a dozen states.
AdventHealth views genomics and personalized medicine as critical to the future of wellness and health care, and we are delighted to collaborate with Sema4 on this important journey, said Dr. Steven R. Smith , chief scientific officer for AdventHealth.
At the center of this precision medicine collaboration, AdventHealth and Sema4 will conduct data structuring and curation of the combined genomic and clinical data, which, along with Sema4 investigative tools, will allow clinicians and scientists to advance research and discovery.

Sema4 and CM Life Sciences Announce the Filing of the Schedule-14A Proxy Statement in Connection with the Proposed Merger

Retrieved on:

Thursday, May 6, 2021

Research, Technology, Finance, Genetics, Clinical trials, Professional services, Software, Health, Science, Other Science, SEC filings, Shareholders, Proxy statement, Statements, Sema4, CM Life Sciences, SEMA4, CM LIFE SCIENCES

Sema4 believes that patients should be treated as partners, and that data should be shared for the benefit of all.

Key Points:

Sema4 believes that patients should be treated as partners, and that data should be shared for the benefit of all.
Neither Sema4 nor CM Life Sciences gives any assurance that either Sema4 or CM Life Sciences or the combined company will achieve its expectations.\nIn connection with the proposed transaction, CM Life Sciences has filed a preliminary proxy statement with the SEC, and CM Life Sciences will file a definitive proxy statement with the SEC, which will be sent to the stockholders of CM Life Sciences.
CM Life Sciences also will file other documents regarding the proposed transaction with the SEC.
Information about CM Life Sciences\xe2\x80\x99 directors and executive officers and their ownership of CM Life Sciences\xe2\x80\x99 securities is set forth in CM Life Sciences\xe2\x80\x99 filings with the SEC.

CM Life Sciences Announces Filing of Amended Annual Report on Form 10-K Relating to Restatement of Financial Statements in Accordance with Recent SEC Guidance

Retrieved on:

Wednesday, May 5, 2021

Data management, Health, Technology, Genetics, Other Science, General Health, Science, SEC filings, Proxy statement, Form 10-K, Documents, CM Life Sciences, Sema4, CM LIFE SCIENCES, SEMA4

In light of such restatement, CM Life Sciences, after consultation with its independent auditors, concluded that the prior audited financial statements referenced in its annual report on Form 10-K should no longer be relied upon.\nCM Life Sciences has entered into a business combination agreement with Sema4, a patient-centered health intelligence company.

Key Points:

In light of such restatement, CM Life Sciences, after consultation with its independent auditors, concluded that the prior audited financial statements referenced in its annual report on Form 10-K should no longer be relied upon.\nCM Life Sciences has entered into a business combination agreement with Sema4, a patient-centered health intelligence company.
Neither Sema4 nor CM Life Sciences gives any assurance that either Sema4 or CM Life Sciences or the combined company will achieve its expectations.\nIn connection with the proposed transaction, CM Life Sciences intends to file a proxy statement with the SEC.
CM Life Sciences also will file other documents regarding the proposed transaction with the SEC.
Information about CM Life Sciences\xe2\x80\x99 directors and executive officers and their ownership of CM Life Sciences\xe2\x80\x99 securities is set forth in CM Life Sciences\xe2\x80\x99 filings with the SEC.